ClinicalTrials.gg
Not yet recruitingNCT07574489Updated Nov 3, 2026

Whole Versus Partial Gland Boost During Prostate SBRT

A Phase 2 interventional study of Prostate stereotactic body radiotherapy with whole gland boost and Prostate stereotactic body radiotherapy with DIL boost in Prostate Cancer and Prostate Adenocarcinoma, sponsored by University of Nebraska. Not yet recruiting at 1 site in United States. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Start date movedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Prostatic Neoplasms by University of Nebraska — 8 open to participants now, 8 under way, none of them phase 3. Prostatic Neoplasms · University of Nebraska.

Planned enrollment
2nd of 11
160 · median 54
Started
2026
with 4 others
Phase 2
6 of 13
5 open now
Registered
10th of 13
by date

Among the 13 studies in Prostatic Neoplasms by University of Nebraska, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, and was the 10th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 13 studies in Prostatic Neoplasms by University of Nebraska are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Prostatic Neoplasms by University of Nebraska, or all of them as a file.
02

Study summary

The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.

Read the detailed description

This is a phase 2 randomized clinical trial evaluating two dose escalation strategies during prostate stereotactic body radiotherapy (SBRT). A total of 160 patients with prostate adenocarcinoma will be enrolled and randomized in a 1:1 ratio to one of two treatment arms.

160 patients will be enrolled in this study over 3.2 years. Eligible participants will be stratified by risk group and tamsulosin use and randomized to one of two treatment arms. Both arms will receive 3625 cGy to the prostate plus planning margin delivered over 5 fractions. Arm A will receive an additional boost of 4000 cGy to the prostate alone. Arm B will receive an additional boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Acute and chronic GU and GI toxicities will be measured, as well as biochemical progression-free survival. Toxicities will be measured using CTCAE, Radiation Therapy Oncology Group, and Expanded Prostate Cancer Index Composite domains.

Participants will be followed for up to 5 years after completion of treatment.

03

Conditions studied

  • Prostate Cancer
  • Prostate Adenocarcinoma

Browse trials for

Keywords

  • Prostate SBRT
  • Stereotactic Body Radiotherapy
  • Dose Escalation
  • Dominant Intraprostatic Lesion
  • DIL
  • Radiation Therapy
  • Genitourinary Toxicity
  • Gastrointestinal Toxicity
  • CTCAE
  • RTOG
  • EPIC
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ≥19 years of age
  2. Patients with a diagnosis of prostate adenocarcinoma for whom SBRT to the prostate +/- proximal seminal vesicles is being offered
  3. Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of or by separate measure with ultrasound or other imaging modalities, including MRI or CT scan
  4. PI-RADS 4 or 5 lesion seen on pretreatment MRI
  5. IPSS/AUA (Appendix D, E) symptom score less than 16

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment for prostate cancer
  2. Prior solid cancer diagnosis in the last 5 years
  3. Any history of anal or rectal cancer
  4. Any history of invasive carcinoma of the bladder
  5. History of prior circumferential resection of the rectum (such as LAR or APR)
  6. History of inflammatory bowel syndromes not adequately controlled on current medication regimen
  7. Urinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Arm A: boost to prostate alone

    Participants assigned to Arm A will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4000 cGy to the clinical target volume (CTV), consisting of the prostate alone without a margin. Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB).

    Radiation: Prostate stereotactic body radiotherapy with whole gland boost

  • Experimental
    Arm B: boost to dominant intra-prostatic lesion (DIL)

    Participants assigned to Arm B will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB).

    Radiation: Prostate stereotactic body radiotherapy with DIL boost

Interventions

  • RadiationProstate stereotactic body radiotherapy with whole gland boost

    External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost

  • RadiationProstate stereotactic body radiotherapy with DIL boost

    External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.

06

What researchers measure

Primary outcomes

  1. Grade 2 or Higher Acute Genitourinary Toxicity

    To evaluate acute genitourinary (GU) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using Common Terminology Criteria for Adverse Events Version 6.0 (CTCAE)

    Time frame: From end of treatment to 3 months post-treatment

Secondary outcomes

  1. Grade 2 or Higher Acute Gastrointestinal Toxicity

    To evaluate gastrointestinal (GI) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using CTCAE

    Time frame: From end of treatment to 3 months post-treatment

  2. Biochemical Progression-Free Survival

    Time from initiation of study treatment to biochemical disease progression or death from any cause

    Time frame: From initiation of study treatment to 5 years post-treatment

  3. Chronic Gastrointestinal Toxicity - Cumulative Incidence

    Cumulative incidence of chronic gastrointestinal (GI) toxicities assessed using CTCAE, Radiation Therapy Oncology Group (RTOG), and Expanded Prostate Cancer Index Composite (EPIC) domains.

    Time frame: From 6 months to 21 months post-treatment

  4. Chronic Genitourinary Toxicity - Cumulative Incidence

    Cumulative incidence of chronic genitourinary (GU) toxicities assessed using CTCAE, RTOG, and EPIC domains.

    Time frame: From 6 months to 21 months post-treatment

  5. Chronic Gastrointestinal Toxicity

    To evaluate chronic GI toxicities at 5 years using CTCAE, RTOG, and EPIC domains.

    Time frame: At 5 years

  6. Chronic Genitourinary Toxicity

    To evaluate chronic GU toxicities at 5 years using CTCAE, RTOG, and EPIC domains.

    Time frame: At 5 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2032, 72 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 72 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start Jul 2026 → Dec 2026, primary completion Aug 2032 → Dec 2032 and completion Aug 2035 → Dec 2035.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 8, 2026
StartEst.
Dec 25, 2026was Jul 2026
Primary completionEst.
Dec 25, 2032was Aug 2032
CompletionEst.
Dec 25, 2035was Aug 2035
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 25, 2026→Dec 25, 2026
Nov 3, 2026
Primary completion
Aug 25, 2032→Dec 25, 2032
Nov 3, 2026
Study completion
Aug 25, 2035→Dec 25, 2035
Nov 3, 2026
Enrollment
186→160
Nov 3, 2026
Eligibility
4 inclusion criteria edited; 1 exclusion criterion edited, 2 added
What changed in the criteria
Inclusion criteria
  • EditedPatients with a diagnosis of prostate adenocarcinoma for which stereotactic body radiotherapy (whom SBRT) to the prostate ±+/- proximal seminal vesicles is being offered
  • EditedProstate gland volume <less than 100 cc prior to initiation of androgen deprivation therapy (ADT), as reported at time of biopsy or by separate measure with ultrasound or other imaging (e.g.modalities, ultrasound,including MRI, or CT) scan
  • EditedPI-RADS 4 or 5 lesion seen on pre-treatmentpretreatment MRI
  • EditedIPSS/AUA (Appendix D, E) symptom score less than 16
Exclusion criteria
  • EditedPrior solid cancer diagnosis withinin the last 5 years
  • AddedHistory of inflammatory bowel syndromes not adequately controlled on current medication regimen
  • AddedUrinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
Nov 3, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedGrade 2 or Higher ChronicAcute Genitourinary ToxicityTime frame: From 6 months post-treatment to 2 years post-treatment → From end of treatment to 3 months post-treatment
  • RemovedGrade 2 or Higher Chronic Gastrointestinal ToxicityTime frame: From 6 months post-treatment to 2 years post-treatment
Nov 3, 2026
Secondary outcomes
1 edited, 2 time frame changed, 2 added, 1 removed, 3 description edited
What changed in the outcomes
  • EditedGrade 2 or Higher Acute Gastrointestinal ToxicityTime frame: From end of treatment to 6 months post-treatment → From end of treatment to 3 months post-treatment
  • AddedChronic Gastrointestinal Toxicity - Cumulative IncidenceTime frame: From 6 months to 21 months post-treatment
  • AddedChronic Genitourinary Toxicity - Cumulative IncidenceTime frame: From 6 months to 21 months post-treatment
  • RemovedAcute Genitourinary ToxicityTime frame: From end of treatment to 6 months post-treatment
  • Time frameChronic Gastrointestinal ToxicityFrom 6 months post-treatment to 5 years post-treatment → At 5 years
  • Time frameChronic Genitourinary ToxicityFrom 6 months post-treatment to 5 years post-treatment → At 5 years
  • DescriptionBiochemical Progression-Free Survival: how it is measured was reworded
  • DescriptionChronic Gastrointestinal Toxicity: how it is measured was reworded
  • DescriptionChronic Genitourinary Toxicity: how it is measured was reworded
Nov 3, 2026
Design
Removed Phase 3
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Start date Jul 25, 2026→Dec 25, 2026
    Primary completion Aug 25, 2032→Dec 25, 2032
    Study completion Aug 25, 2035→Dec 25, 2035
    Enrollment 186→160
    Eligibility 4 inclusion criteria edited; 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with a diagnosis of prostate adenocarcinoma for which stereotactic body radiotherapy (whom SBRT) to the prostate ±+/- proximal seminal vesicles is being offered
    • EditedProstate gland volume <less than 100 cc prior to initiation of androgen deprivation therapy (ADT), as reported at time of biopsy or by separate measure with ultrasound or other imaging (e.g.modalities, ultrasound,including MRI, or CT) scan
    • EditedPI-RADS 4 or 5 lesion seen on pre-treatmentpretreatment MRI
    • EditedIPSS/AUA (Appendix D, E) symptom score less than 16
    Exclusion criteria
    • EditedPrior solid cancer diagnosis withinin the last 5 years
    • AddedHistory of inflammatory bowel syndromes not adequately controlled on current medication regimen
    • AddedUrinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedGrade 2 or Higher ChronicAcute Genitourinary ToxicityTime frame: From 6 months post-treatment to 2 years post-treatment → From end of treatment to 3 months post-treatment
    • RemovedGrade 2 or Higher Chronic Gastrointestinal ToxicityTime frame: From 6 months post-treatment to 2 years post-treatment
    Secondary outcomes 1 edited, 2 time frame changed, 2 added, 1 removed, 3 description edited
    What changed in the outcomes
    • EditedGrade 2 or Higher Acute Gastrointestinal ToxicityTime frame: From end of treatment to 6 months post-treatment → From end of treatment to 3 months post-treatment
    • AddedChronic Gastrointestinal Toxicity - Cumulative IncidenceTime frame: From 6 months to 21 months post-treatment
    • AddedChronic Genitourinary Toxicity - Cumulative IncidenceTime frame: From 6 months to 21 months post-treatment
    • RemovedAcute Genitourinary ToxicityTime frame: From end of treatment to 6 months post-treatment
    • Time frameChronic Gastrointestinal ToxicityFrom 6 months post-treatment to 5 years post-treatment → At 5 years
    • Time frameChronic Genitourinary ToxicityFrom 6 months post-treatment to 5 years post-treatment → At 5 years
    • DescriptionBiochemical Progression-Free Survival: how it is measured was reworded
    • DescriptionChronic Gastrointestinal Toxicity: how it is measured was reworded
    • DescriptionChronic Genitourinary Toxicity: how it is measured was reworded
    Design Removed Phase 3
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07574489
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Dec 25, 2026 (estimated)
Primary completion
Dec 25, 2032 (estimated)
Completion
Dec 25, 2035 (estimated)
Last update
Nov 3, 2026

Study contacts

Krishna Gottipati, MS
Contact
krgottipati@unmc.edu
4025593518
IIT Office Gottipati
Contact
IITOFFICE@unmc.edu
4025590963
Michael Baine, MD, PhD
principal investigator · University of Nebraska medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion